Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 79 entries
Sorted by: Best Match Show Resources per page
Sucralfate gel as a radioprotector against radiation induced dermatitis in a hypo-fractionated schedule: a non-randomized study.

Hippokratia

Kouloulias V, Asimakopoulos C, Tolia M, Filippou G, Platoni K, Dilvoi M, Beli I, Georgakopoulos J, Patatoukas G, Kelekis N.
PMID: 24376316
Hippokratia. 2013 Apr;17(2):126-9.

External beam radiotherapy with high doses provokes many acute skin reactions, such as erythema and moist desquamation. Many topical preparations are used in radiation oncology departments in the skin care. Sucralfate humid gel, a colloidal physical form of the...

Cite
Kouloulias V, Asimakopoulos C, Tolia M, et al. Sucralfate gel as a radioprotector against radiation induced dermatitis in a hypo-fractionated schedule: a non-randomized study. Hippokratia. 2013;17(2):126-9
Kouloulias, V., Asimakopoulos, C., Tolia, M., Filippou, G., Platoni, K., Dilvoi, M., Beli, I., Georgakopoulos, J., Patatoukas, G., & Kelekis, N. (2013). Sucralfate gel as a radioprotector against radiation induced dermatitis in a hypo-fractionated schedule: a non-randomized study. Hippokratia, 17(2), 126-9.
Kouloulias, V, et al. "Sucralfate gel as a radioprotector against radiation induced dermatitis in a hypo-fractionated schedule: a non-randomized study." Hippokratia vol. 17,2 (2013): 126-9.
Kouloulias V, Asimakopoulos C, Tolia M, Filippou G, Platoni K, Dilvoi M, Beli I, Georgakopoulos J, Patatoukas G, Kelekis N. Sucralfate gel as a radioprotector against radiation induced dermatitis in a hypo-fractionated schedule: a non-randomized study. Hippokratia. 2013 Apr;17(2):126-9. PMID: 24376316; PMCID: PMC3743615.
Copy Download .nbib Format: NLM
Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiation therapy.

Molecular and clinical oncology

Memtsa PT, Tolia M, Tzitzikas I, Bizakis J, Pistevou-Gombaki K, Charalambidou M, Iliopoulou C, Kyrgias G.
PMID: 28529753
Mol Clin Oncol. 2017 May;6(5):789-793. doi: 10.3892/mco.2017.1200. Epub 2017 Mar 17.

Xerostomia in head and neck (H&N) cancer patients significantly affects their quality of life (QoL). The aim of the present study was to investigate the associations among QoL, xerostomia and quantity of saliva in a sample of H&N cancer...

Cite
Memtsa PT, Tolia M, Tzitzikas I, et al. Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiation therapy. Mol Clin Oncol. 2017;6(5):789-793doi: 10.3892/mco.2017.1200.
Memtsa, P. T., Tolia, M., Tzitzikas, I., Bizakis, J., Pistevou-Gombaki, K., Charalambidou, M., Iliopoulou, C., & Kyrgias, G. (2017). Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiation therapy. Molecular and clinical oncology, 6(5), 789-793. https://doi.org/10.3892/mco.2017.1200
Memtsa, Pinelopi-Theopisti, et al. "Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiation therapy." Molecular and clinical oncology vol. 6,5 (2017): 789-793. doi: https://doi.org/10.3892/mco.2017.1200
Memtsa PT, Tolia M, Tzitzikas I, Bizakis J, Pistevou-Gombaki K, Charalambidou M, Iliopoulou C, Kyrgias G. Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiation therapy. Mol Clin Oncol. 2017 May;6(5):789-793. doi: 10.3892/mco.2017.1200. Epub 2017 Mar 17. PMID: 28529753; PMCID: PMC5431738.
Copy Download .nbib Format: NLM
Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial.

Evidence-based complementary and alternative medicine : eCAM

Vosough-Ghanbari S, Rahimi R, Kharabaf S, Zeinali S, Mohammadirad A, Amini S, Yasa N, Salehnia A, Toliat T, Nikfar S, Larijani B, Abdollahi M.
PMID: 18955324
Evid Based Complement Alternat Med. 2010 Dec;7(4):465-70. doi: 10.1093/ecam/nen018. Epub 2008 Feb 27.

Satureja khuzestanica is an endemic plant of Iran that is widely distributed in the Southern part of the country. It has antioxidant properties and thus it seems to be useful in diseases related to oxidative stress such as diabetes...

Cite
Vosough-Ghanbari S, Rahimi R, Kharabaf S, et al. Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial. Evid Based Complement Alternat Med. 2008;7(4):465-70doi: 10.1093/ecam/nen018.
Vosough-Ghanbari, S., Rahimi, R., Kharabaf, S., Zeinali, S., Mohammadirad, A., Amini, S., Yasa, N., Salehnia, A., Toliat, T., Nikfar, S., Larijani, B., & Abdollahi, M. (2010). Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial. Evidence-based complementary and alternative medicine : eCAM, 7(4), 465-70. https://doi.org/10.1093/ecam/nen018
Vosough-Ghanbari, Sanaz, et al. "Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial." Evidence-based complementary and alternative medicine : eCAM vol. 7,4 (2010): 465-70. doi: https://doi.org/10.1093/ecam/nen018
Vosough-Ghanbari S, Rahimi R, Kharabaf S, Zeinali S, Mohammadirad A, Amini S, Yasa N, Salehnia A, Toliat T, Nikfar S, Larijani B, Abdollahi M. Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial. Evid Based Complement Alternat Med. 2010 Dec;7(4):465-70. doi: 10.1093/ecam/nen018. Epub 2008 Feb 27. PMID: 18955324; PMCID: PMC2892343.
Copy Download .nbib Format: NLM
Cholangitis with large common bile duct dilatation caused by choledochal macrolithiasis.

Annals of gastroenterology

Joliat GR, Winiker M, Antonino AT, Galasso D.
PMID: 32624669
Ann Gastroenterol. 2020 Jul-Aug;33(4):438. doi: 10.20524/aog.2020.0471. Epub 2020 Mar 27.

No abstract available.

Cite
Joliat GR, Winiker M, Antonino AT, et al. Cholangitis with large common bile duct dilatation caused by choledochal macrolithiasis. Ann Gastroenterol. 2020;33(4):438doi: 10.20524/aog.2020.0471.
Joliat, G. R., Winiker, M., Antonino, A. T., & Galasso, D. (2020). Cholangitis with large common bile duct dilatation caused by choledochal macrolithiasis. Annals of gastroenterology, 33(4), 438. https://doi.org/10.20524/aog.2020.0471
Joliat, Gaëtan-Romain, et al. "Cholangitis with large common bile duct dilatation caused by choledochal macrolithiasis." Annals of gastroenterology vol. 33,4 (2020): 438. doi: https://doi.org/10.20524/aog.2020.0471
Joliat GR, Winiker M, Antonino AT, Galasso D. Cholangitis with large common bile duct dilatation caused by choledochal macrolithiasis. Ann Gastroenterol. 2020 Jul-Aug;33(4):438. doi: 10.20524/aog.2020.0471. Epub 2020 Mar 27. PMID: 32624669; PMCID: PMC7315712.
Copy Download .nbib Format: NLM
A 24-generation-old founder mutation impairs splicing of RBBP8 in Pakistani families affected with Jawad syndrome.

Clinical genetics

Kaygusuz E, Khayyat AIA, Abdullah U, Budde BS, Asif M, Ahmed I, Makhdoom EUH, Sur-Erdem I, Baig JM, Khan MMA, Toliat MR, Becker C, Anwar H, Iqbal M, Fischer S, Jameel M, Sher M, Tariq M, Malik NA, Noegel AA, Hassan MJ, Thiele H, Tinschert S, Eichinger L, Höning S, Baig SM, Nürnberg P, Hussain MS.
PMID: 34270086
Clin Genet. 2021 Oct;100(4):486-488. doi: 10.1111/cge.14028. Epub 2021 Jul 16.

Jawad syndrome is a multiple congenital anomaly and intellectual disability syndrome with mutation in RBBP8 reported only in two families. Here, we report on two new families from Pakistan and identified a previously reported variant in RBBP8, NM_002894.3:c.1808-1809delTA. We...

Cite
Kaygusuz E, Khayyat AIA, Abdullah U, et al. A 24-generation-old founder mutation impairs splicing of RBBP8 in Pakistani families affected with Jawad syndrome. Clin Genet. 2021;100(4):486-488doi: 10.1111/cge.14028.
Kaygusuz, E., Khayyat, A. I. A., Abdullah, U., Budde, B. S., Asif, M., Ahmed, I., Makhdoom, E. U. H., Sur-Erdem, I., Baig, J. M., Khan, M. M. A., Toliat, M. R., Becker, C., Anwar, H., Iqbal, M., Fischer, S., Jameel, M., Sher, M., Tariq, M., Malik, N. A., Noegel, A. A., Hassan, M. J., Thiele, H., Tinschert, S., Eichinger, L., Höning, S., Baig, S. M., Nürnberg, P., & Hussain, M. S. (2021). A 24-generation-old founder mutation impairs splicing of RBBP8 in Pakistani families affected with Jawad syndrome. Clinical genetics, 100(4), 486-488. https://doi.org/10.1111/cge.14028
Kaygusuz, Emrah, et al. "A 24-generation-old founder mutation impairs splicing of RBBP8 in Pakistani families affected with Jawad syndrome." Clinical genetics vol. 100,4 (2021): 486-488. doi: https://doi.org/10.1111/cge.14028
Kaygusuz E, Khayyat AIA, Abdullah U, Budde BS, Asif M, Ahmed I, Makhdoom EUH, Sur-Erdem I, Baig JM, Khan MMA, Toliat MR, Becker C, Anwar H, Iqbal M, Fischer S, Jameel M, Sher M, Tariq M, Malik NA, Noegel AA, Hassan MJ, Thiele H, Tinschert S, Eichinger L, Höning S, Baig SM, Nürnberg P, Hussain MS. A 24-generation-old founder mutation impairs splicing of RBBP8 in Pakistani families affected with Jawad syndrome. Clin Genet. 2021 Oct;100(4):486-488. doi: 10.1111/cge.14028. Epub 2021 Jul 16. PMID: 34270086.
Copy Download .nbib Format: NLM
Next Generation Sequencing of Circulating Tumor DNA Can Optimize Second Line Treatment in RAS Wild Type Metastatic Colorectal Cancer after Progression on Anti-EGFR Therapy: Time to Rethink Our Approach.

Oncology research and treatment

Mauri D, Kamposioras K, Matthaios D, Tolia M, Nixon I, Dambrosio M, Zarkavelis G, Papadimitriou K, Petricevic B, Kountourakis P, Kopecky J, Grašič Kuhar C, Popovic L, Chilingirova NP, De Mello RA, Dedic N, Katsanos K, Mostert B, Alongi F, de Bari B, Corradini S, Kampletsas E, Gazouli I, Gkoura S, Amylidi AL, Valachis A.
PMID: 34999585
Oncol Res Treat. 2022 Jan 09; doi: 10.1159/000521845. Epub 2022 Jan 09.

Background Management of Raswild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge. Development of treatment resistance with prevalence of pre-existing RAS mutated...

Cite
Mauri D, Kamposioras K, Matthaios D, et al. Next Generation Sequencing of Circulating Tumor DNA Can Optimize Second Line Treatment in RAS Wild Type Metastatic Colorectal Cancer after Progression on Anti-EGFR Therapy: Time to Rethink Our Approach. Oncol Res Treat. 2022;doi: 10.1159/000521845.
Mauri, D., Kamposioras, K., Matthaios, D., Tolia, M., Nixon, I., Dambrosio, M., Zarkavelis, G., Papadimitriou, K., Petricevic, B., Kountourakis, P., Kopecky, J., Grašič Kuhar, C., Popovic, L., Chilingirova, N. P., De Mello, R. A., Dedic, N., Katsanos, K., Mostert, B., Alongi, F., de Bari, B., Corradini, S., Kampletsas, E., Gazouli, I., Gkoura, S., Amylidi, A. L., & Valachis, A. (2022). Next Generation Sequencing of Circulating Tumor DNA Can Optimize Second Line Treatment in RAS Wild Type Metastatic Colorectal Cancer after Progression on Anti-EGFR Therapy: Time to Rethink Our Approach. Oncology research and treatment, . https://doi.org/10.1159/000521845
Mauri, Davide, et al. "Next Generation Sequencing of Circulating Tumor DNA Can Optimize Second Line Treatment in RAS Wild Type Metastatic Colorectal Cancer after Progression on Anti-EGFR Therapy: Time to Rethink Our Approach." Oncology research and treatment vol. (2022). doi: https://doi.org/10.1159/000521845
Mauri D, Kamposioras K, Matthaios D, Tolia M, Nixon I, Dambrosio M, Zarkavelis G, Papadimitriou K, Petricevic B, Kountourakis P, Kopecky J, Grašič Kuhar C, Popovic L, Chilingirova NP, De Mello RA, Dedic N, Katsanos K, Mostert B, Alongi F, de Bari B, Corradini S, Kampletsas E, Gazouli I, Gkoura S, Amylidi AL, Valachis A. Next Generation Sequencing of Circulating Tumor DNA Can Optimize Second Line Treatment in RAS Wild Type Metastatic Colorectal Cancer after Progression on Anti-EGFR Therapy: Time to Rethink Our Approach. Oncol Res Treat. 2022 Jan 09; doi: 10.1159/000521845. Epub 2022 Jan 09. PMID: 34999585.
Copy Download .nbib Format: NLM
A Randomized Trial of Brief Online Interventions to Facilitate Treatment Seeking for Social Anxiety.

Behavior modification

Tobias MR, Landy LN, Levin ME, Arch JJ.
PMID: 34459271
Behav Modif. 2021 Aug 28;1454455211040051. doi: 10.1177/01454455211040051. Epub 2021 Aug 28.

This study developed and evaluated a brief, single-session online intervention designed to facilitate treatment seeking among adults with clinically significant social anxiety (SA) symptoms, who generally seek treatment at exceptionally low rates. Adults (

Cite
Tobias MR, Landy LN, Levin ME, et al. A Randomized Trial of Brief Online Interventions to Facilitate Treatment Seeking for Social Anxiety. Behav Modif. 2021;1454455211040051doi: 10.1177/01454455211040051.
Tobias, M. R., Landy, L. N., Levin, M. E., & Arch, J. J. (2021). A Randomized Trial of Brief Online Interventions to Facilitate Treatment Seeking for Social Anxiety. Behavior modification, 1454455211040051. https://doi.org/10.1177/01454455211040051
Tobias, Margaret R, et al. "A Randomized Trial of Brief Online Interventions to Facilitate Treatment Seeking for Social Anxiety." Behavior modification vol. (2021): 1454455211040051. doi: https://doi.org/10.1177/01454455211040051
Tobias MR, Landy LN, Levin ME, Arch JJ. A Randomized Trial of Brief Online Interventions to Facilitate Treatment Seeking for Social Anxiety. Behav Modif. 2021 Aug 28;1454455211040051. doi: 10.1177/01454455211040051. Epub 2021 Aug 28. PMID: 34459271.
Copy Download .nbib Format: NLM
Immunotherapy for cholangiocarcinoma: a 2021 update.

Immunotherapy

Charalampakis N, Papageorgiou G, Tsakatikas S, Fioretzaki R, Kole C, Kykalos S, Tolia M, Schizas D.
PMID: 34190581
Immunotherapy. 2021 Sep;13(13):1113-1134. doi: 10.2217/imt-2021-0126. Epub 2021 Jun 30.

Cholangiocarcinoma (CCA) is a rare malignancy with generally dismal prognosis. Immunotherapy has revolutionized the management of cancer patients during the last decade, offering durable responses with an acceptable safety profile, but there are still no significant advances regarding CCA....

Cite
Charalampakis N, Papageorgiou G, Tsakatikas S, et al. Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy. 2021;13(13):1113-1134doi: 10.2217/imt-2021-0126.
Charalampakis, N., Papageorgiou, G., Tsakatikas, S., Fioretzaki, R., Kole, C., Kykalos, S., Tolia, M., & Schizas, D. (2021). Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy, 13(13), 1113-1134. https://doi.org/10.2217/imt-2021-0126
Charalampakis, Nikolaos, et al. "Immunotherapy for cholangiocarcinoma: a 2021 update." Immunotherapy vol. 13,13 (2021): 1113-1134. doi: https://doi.org/10.2217/imt-2021-0126
Charalampakis N, Papageorgiou G, Tsakatikas S, Fioretzaki R, Kole C, Kykalos S, Tolia M, Schizas D. Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy. 2021 Sep;13(13):1113-1134. doi: 10.2217/imt-2021-0126. Epub 2021 Jun 30. PMID: 34190581.
Copy Download .nbib Format: NLM
YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango.

Biomedicines

Matthaios D, Tolia M, Mauri D, Kamposioras K, Karamouzis M.
PMID: 34944765
Biomedicines. 2021 Dec 20;9(12). doi: 10.3390/biomedicines9121949.

Hippo pathway with its main molecule YAP is a crucial pathway for development, tissue homeostasis, wound healing, tissue regeneration, and cancer. In this review, we discuss the multiple effects of the YAP/Hippo pathway in the immune system and cancer....

Cite
Matthaios D, Tolia M, Mauri D, et al. YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Biomedicines. 2021;9(12)doi: 10.3390/biomedicines9121949.
Matthaios, D., Tolia, M., Mauri, D., Kamposioras, K., & Karamouzis, M. (2021). YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Biomedicines, 9(12), . https://doi.org/10.3390/biomedicines9121949
Matthaios, Dimitrios, et al. "YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango." Biomedicines vol. 9,12 (2021). doi: https://doi.org/10.3390/biomedicines9121949
Matthaios D, Tolia M, Mauri D, Kamposioras K, Karamouzis M. YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Biomedicines. 2021 Dec 20;9(12). doi: 10.3390/biomedicines9121949. PMID: 34944765; PMCID: PMC8698579.
Copy Download .nbib Format: NLM
YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango.

Biomedicines

Matthaios D, Tolia M, Mauri D, Kamposioras K, Karamouzis M.
PMID: 34944765
Biomedicines. 2021 Dec 20;9(12). doi: 10.3390/biomedicines9121949.

Hippo pathway with its main molecule YAP is a crucial pathway for development, tissue homeostasis, wound healing, tissue regeneration, and cancer. In this review, we discuss the multiple effects of the YAP/Hippo pathway in the immune system and cancer....

Cite
Matthaios D, Tolia M, Mauri D, et al. YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Biomedicines. 2021;9(12)doi: 10.3390/biomedicines9121949.
Matthaios, D., Tolia, M., Mauri, D., Kamposioras, K., & Karamouzis, M. (2021). YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Biomedicines, 9(12), . https://doi.org/10.3390/biomedicines9121949
Matthaios, Dimitrios, et al. "YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango." Biomedicines vol. 9,12 (2021). doi: https://doi.org/10.3390/biomedicines9121949
Matthaios D, Tolia M, Mauri D, Kamposioras K, Karamouzis M. YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Biomedicines. 2021 Dec 20;9(12). doi: 10.3390/biomedicines9121949. PMID: 34944765.
Copy Download .nbib Format: NLM
COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information.

Reviews on recent clinical trials

Davide M, Kamposioras K, Lampriani T, Mario D, Berardino B, Nadia H, Carl S, Joanna N, Dimitrios T, Flippo A, Hassan H, Antonios V, Konstantinos P, Stefanie C, Lazar P, Jindrich K, Andres R, Katarina A, Junlin Y, Lovey J, Primoz S, Haytham S, Ranveig R, Marzanna C, Olalla SC, Natalia C, Ramon A M, Giovanna AA, Farsid A, Radu V, Erjeta R, D T, Chirstos C, Irina I, Igor D, Branka P, Francesco C, Iglika M, Natalija DP, Cvetka GK, Elena T, Pantelis K, Panagiotis N, Ioanna G, Stefania G, Salih Y, Er Ö, Yasmina C, Kumaran G, Orges S, Aasim Y, Gono P, Apostolidis K, Tolia M.
PMID: 34967300
Rev Recent Clin Trials. 2021 Oct 28; doi: 10.2174/1574887116666211028145848. Epub 2021 Oct 28.

BACKGROUND: Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the...

Cite
Davide M, Kamposioras K, Lampriani T, et al. COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information. Rev Recent Clin Trials. 2021;doi: 10.2174/1574887116666211028145848.
Davide, M., Kamposioras, K., Lampriani, T., Mario, D., Berardino, B., Nadia, H., Carl, S., Joanna, N., Dimitrios, T., Flippo, A., Hassan, H., Antonios, V., Konstantinos, P., Stefanie, C., Lazar, P., Jindrich, K., Andres, R., Katarina, A., Junlin, Y., Lovey, J., Primoz, S., Haytham, S., Ranveig, R., Marzanna, C., Olalla, S. C., Natalia, C., Ramon A, M., Giovanna, A. A., Farsid, A., Radu, V., Erjeta, R., D, T., Chirstos, C., Irina, I., Igor, D., Branka, P., Francesco, C., Iglika, M., Natalija, D. P., Cvetka, G. K., Elena, T., Pantelis, K., Panagiotis, N., Ioanna, G., Stefania, G., Salih, Y., Er, �. �., Yasmina, C., Kumaran, G., Orges, S., Aasim, Y., Gono, P., Apostolidis, K., & Tolia, M. (2021). COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information. Reviews on recent clinical trials, . https://doi.org/10.2174/1574887116666211028145848
Davide, Mauri, et al. "COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information." Reviews on recent clinical trials vol. (2021). doi: https://doi.org/10.2174/1574887116666211028145848
Davide M, Kamposioras K, Lampriani T, Mario D, Berardino B, Nadia H, Carl S, Joanna N, Dimitrios T, Flippo A, Hassan H, Antonios V, Konstantinos P, Stefanie C, Lazar P, Jindrich K, Andres R, Katarina A, Junlin Y, Lovey J, Primoz S, Haytham S, Ranveig R, Marzanna C, Olalla SC, Natalia C, Ramon A M, Giovanna AA, Farsid A, Radu V, Erjeta R, D T, Chirstos C, Irina I, Igor D, Branka P, Francesco C, Iglika M, Natalija DP, Cvetka GK, Elena T, Pantelis K, Panagiotis N, Ioanna G, Stefania G, Salih Y, Er Ö, Yasmina C, Kumaran G, Orges S, Aasim Y, Gono P, Apostolidis K, Tolia M. COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information. Rev Recent Clin Trials. 2021 Oct 28; doi: 10.2174/1574887116666211028145848. Epub 2021 Oct 28. PMID: 34967300.
Copy Download .nbib Format: NLM
EUS-guided gastrogastrostomy and gastroduodenal stenting for gastric cancer after Roux-en-Y gastric bypass (with video).

Endoscopic ultrasound

Joliat GR, Dayer A, Garin N, Galasso D.
PMID: 32883922
Endosc Ultrasound. 2020 Sep-Oct;9(5):345-346. doi: 10.4103/eus.eus_53_20.

No abstract available.

Cite
Joliat GR, Dayer A, Garin N, et al. EUS-guided gastrogastrostomy and gastroduodenal stenting for gastric cancer after Roux-en-Y gastric bypass (with video). Endosc Ultrasound. 2020;9(5):345-346doi: 10.4103/eus.eus_53_20.
Joliat, G. R., Dayer, A., Garin, N., & Galasso, D. (2020). EUS-guided gastrogastrostomy and gastroduodenal stenting for gastric cancer after Roux-en-Y gastric bypass (with video). Endoscopic ultrasound, 9(5), 345-346. https://doi.org/10.4103/eus.eus_53_20
Joliat, Gaetan-Romain, et al. "EUS-guided gastrogastrostomy and gastroduodenal stenting for gastric cancer after Roux-en-Y gastric bypass (with video)." Endoscopic ultrasound vol. 9,5 (2020): 345-346. doi: https://doi.org/10.4103/eus.eus_53_20
Joliat GR, Dayer A, Garin N, Galasso D. EUS-guided gastrogastrostomy and gastroduodenal stenting for gastric cancer after Roux-en-Y gastric bypass (with video). Endosc Ultrasound. 2020 Sep-Oct;9(5):345-346. doi: 10.4103/eus.eus_53_20. PMID: 32883922; PMCID: PMC7811722.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 79 entries